News Column

BRIEF: Seattle biotech Oncothyreon pays $27M for Alpine Bio

August 11, 2014

The Seattle Times



Aug. 11--Seattle biotechnology company Oncothyreon has acquired another local firm, Alpine Biosciences, for about $27 million in stock.

Alpine Biosciences, an early stage company that has not advanced any drugs into clinical trials, was formed by Mitch Gold, who stepped down as CEO of Dendreon in 2012, and Jay Venkatesan, a doctor and biotech investment manager. The company has licensed nanoparticle technology it says can "encapsulate" large drug molecules and deliver them to targeted cells for treating diseases.

The 9.3 million shares paid for Alpine represent about one eighth of the company's currently outstanding stock. Oncothyreon, which has a market capitalization of about $216 million, said Venkatesan will join the company as an executive vice president.

Oncothyreon has several cancer drugs in clinical trials, and collaboration deals with larger biotech and pharmaceutical companies.

___

(c)2014 The Seattle Times

Visit The Seattle Times at www.seattletimes.com

Distributed by MCT Information Services


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Seattle Times (WA)


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters